# Saihe Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/saihe-biotechnology

- Industry: Healthcare Specialists
- Headquarters: Hangzhou, China
- Latest round: Angel (Mar 6, 2026)
- Investors on record: 2

## About

Based in Hangzhou, China and founded in 2024, Hangzhou Saihe Biotechnology Co., Ltd., Saihe Biotechnology, is a radiopharmaceutical development company. The company's founder, Dr. Yang Liu, holds a Ph.D. in Chemistry and an M.S. in Biomedical Engineering from Duke University and is currently a researcher at the Wenzhou Research Institute of the Chinese Academy of Sciences. In March 2026, Saihe Biotechnology closed Angel+ funding led by FIRHealth Capital, with participation from Longtai Investment.

The company’s main business is the research and development of innovative drugs in the field of radioactive drugs and the R&D of radionuclide coupling platform technology. The company’s self-developed product is a novel targeted delivery platform for the coupling of halogen diagnostic and therapeutic radioisotopes. Its products are used in the field of cancer diagnosis and treatment.
The company generates revenue by providing research and development services related to radiopharmaceuticals and by selling anti-cancer drugs.
The Angel+ funding raised in March 2026 will be used to accelerate clinical trials of the company's core pipeline and recruit professional talent to research and develop innovative nuclear medicine technologies, creating potent and specific new cancer treatments to benefit cancer patients.

## Funding rounds

- Angel, Mar 6, 2026 — Longtai Investment, FIRHealth Capital
- Angel, Nov 21, 2024 — FIRHealth Capital

## Investors

- FIRHealth Capital (https://capitalatlas.ai/funds/firhealth-capital) — Angel
- Longtai Investment (https://capitalatlas.ai/funds/longtai-investment) — Angel